Demographics for 115 randomized subjects by treatment arm reported as median (IQR) except as stated
| . | LD (n = 58) . | HD (n = 57) . | P . |
|---|---|---|---|
| Randomization age, mo | 15.6 (10.7-23.2) | 14.4 (11.4-25.3) | .75 |
| Diagnostic inhibitor titer, BU/mL | 9.9 (5.0-18.2) | 11.5 (6.3-23.0) | .52 |
| Peak historical inhibitor titer, BU/mL | 21.7 (13.4-52.5) | 22.4 (12.5-50.0) | .78 |
| Inhibitor titer at randomization, BU/mL | 5.9 (3.3-7.3) | 5.1 (3.0-7.4) | .85 |
| Peak inhibitor titer on ITI, BU/mL* | 40.1 (7.6-150) | 33.0 (1.5-205) | .37 |
| Total time on ITI, mo* | 16.4 (10.5-22.4) | 14.2 (9.1-22.6) | .70 |
| Ethnicity, n† | |||
| White | 32 | 27 | |
| African | 5 | 4 | |
| Asian | 12 | 11 | |
| Other | 9 | 14 | |
| . | LD (n = 58) . | HD (n = 57) . | P . |
|---|---|---|---|
| Randomization age, mo | 15.6 (10.7-23.2) | 14.4 (11.4-25.3) | .75 |
| Diagnostic inhibitor titer, BU/mL | 9.9 (5.0-18.2) | 11.5 (6.3-23.0) | .52 |
| Peak historical inhibitor titer, BU/mL | 21.7 (13.4-52.5) | 22.4 (12.5-50.0) | .78 |
| Inhibitor titer at randomization, BU/mL | 5.9 (3.3-7.3) | 5.1 (3.0-7.4) | .85 |
| Peak inhibitor titer on ITI, BU/mL* | 40.1 (7.6-150) | 33.0 (1.5-205) | .37 |
| Total time on ITI, mo* | 16.4 (10.5-22.4) | 14.2 (9.1-22.6) | .70 |
| Ethnicity, n† | |||
| White | 32 | 27 | |
| African | 5 | 4 | |
| Asian | 12 | 11 | |
| Other | 9 | 14 | |